Tandem repeat variation near the HIC1 (hypermethylated in cancer 1) promoter predicts outcome of oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer

Satoshi Okazaki, Marta Schirripa, Fotios Loupakis, Shu Cao, Wu Zhang, Dongyun Yang, Yan Ning, Martin D. Berger, Yuji Miyamoto, Mitsukuni Suenaga, Syma Iqubal, Afsaneh Barzi, Chiara Cremolini, Alfredo Falcone, Francesca Battaglin, Lisa Salvatore, Beatrice Borelli, Timothy G. Helentjaris, Heinz Josef Lenz

Research output: Contribution to journalArticle

Abstract

BACKGROUND: The hypermethylated in cancer 1/sirtuin 1 (HIC1/SIRT1) axis plays an important role in regulating the nucleotide excision repair pathway, which is the main oxaliplatin-induced damage-repair system. On the basis of prior evidence that the variable number of tandem repeat (VNTR) sequence located near the promoter lesion of HIC1 is associated with HIC1 gene expression, the authors tested the hypothesis that this VNTR is associated with clinical outcome in patients with metastatic colorectal cancer who receive oxaliplatin-based chemotherapy. METHODS: Four independent cohorts were tested. Patients who received oxaliplatin-based chemotherapy served as the training cohort (n = 218), and those who received treatment without oxaliplatin served as the control cohort (n = 215). Two cohorts of patients who received oxaliplatin-based chemotherapy were used for validation studies (n = 176 and n = 73). The VNTR sequence near HIC1 was analyzed by polymerase chain reaction analysis and gel electrophoresis and was tested for associations with the response rate, progression-free survival, and overall survival. RESULTS: In the training cohort, patients who harbored at least 5 tandem repeats (TRs) in both alleles had a significantly shorter PFS compared with those who had fewer than 4 TRs in at least 1 allele (9.5 vs 11.6 months; hazard ratio, 1.93; P =.012), and these findings remained statistically significant after multivariate analysis (hazard ratio, 2.00; 95% confidence interval, 1.13-3.54; P =.018). This preliminary association was confirmed in the validation cohort, and patients who had at least 5 TRs in both alleles had a worse PFS compared with the other cohort (7.9 vs 9.8 months; hazard ratio, 1.85; P =.044). CONCLUSIONS: The current findings suggest that the VNTR sequence near HIC1 could be a predictive marker for oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Cancer 2017;123:4506-14.

Original languageEnglish
Pages (from-to)4506-4514
Number of pages9
JournalCancer
Volume123
Issue number22
DOIs
Publication statusPublished - Nov 15 2017

Keywords

  • hypermethylated in cancer 1 (HIC1)
  • metastatic colorectal cancer
  • oxaliplatin
  • predictive marker
  • variable number of tandem repeat (VNTR) polymorphism

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Tandem repeat variation near the HIC1 (hypermethylated in cancer 1) promoter predicts outcome of oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer'. Together they form a unique fingerprint.

  • Cite this

    Okazaki, S., Schirripa, M., Loupakis, F., Cao, S., Zhang, W., Yang, D., Ning, Y., Berger, M. D., Miyamoto, Y., Suenaga, M., Iqubal, S., Barzi, A., Cremolini, C., Falcone, A., Battaglin, F., Salvatore, L., Borelli, B., Helentjaris, T. G., & Lenz, H. J. (2017). Tandem repeat variation near the HIC1 (hypermethylated in cancer 1) promoter predicts outcome of oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Cancer, 123(22), 4506-4514. https://doi.org/10.1002/cncr.30880